Jump to content

Metallopharmaceutical

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 02:09, 30 July 2021 (Add: s2cid. | Use this bot. Report bugs. | Suggested by Abductive | Category:Pharmacology stubs‎ | #UCB_Category 346/606). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Carboplatin, an example of a metallopharmaceutical

A metallopharmaceutical is a drug that contains a metal as an active ingredient.[1][2] Most commonly metallopharmaceuticals are used as anticancer or antimicrobial agents. The efficiency of metallopharmaceuticals is crucially dependent on the respective trace metal binding forms.[3]

Examples of metallopharmaceuticals include:

References

  1. ^ Guo J, Sadler PJ (1999). Medicinal Inorganic Chemistry. Advances in Inorganic Chemistry. Vol. 49. pp. 183–306. doi:10.1016/S0898-8838(08)60271-8. ISBN 9780120236497. {{cite book}}: |journal= ignored (help)
  2. ^ Ray S, Mohan R, Singh JK, Samantaray MK, Shaikh MM, Panda D, Ghosh P (December 2007). "Anticancer and antimicrobial metallopharmaceutical agents based on palladium, gold, and silver N-heterocyclic carbene complexes". J. Am. Chem. Soc. 129 (48): 15042–53. doi:10.1021/ja075889z. PMID 17988129.
  3. ^ Günther K, Weber G (1999). Element speciation analysis: an overview. Analytiker-Taschenbuch. Vol. 20. pp. 71–103. doi:10.1007/978-3-642-59914-9_3. ISBN 978-3-642-64181-7.
  4. ^ Fischbach L, Evans EL (August 2007). "Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori". Aliment. Pharmacol. Ther. 26 (3): 343–57. doi:10.1111/j.1365-2036.2007.03386.x. PMID 17635369.
  5. ^ Graham DY, Shiotani A (June 2008). "New concepts of resistance in the treatment of Helicobacter pylori infections". Nat. Clin. Pract. Gastroenterol. Hepatol. 5 (6): 321–31. doi:10.1038/ncpgasthep1138. PMC 2841357. PMID 18446147.
  6. ^ Lokich J, Anderson N (January 1998). "Carboplatin versus cisplatin in solid tumors: an analysis of the literature". Ann. Oncol. 9 (1): 13–21. doi:10.1023/A:1008215213739. PMID 9541678.
  7. ^ Go RS, Adjei AA (January 1999). "Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin". J. Clin. Oncol. 17 (1): 409–22. doi:10.1200/JCO.1999.17.1.409. PMID 10458260.
  8. ^ Messori L, Marcon G (2004). "Gold complexes in the treatment of rheumatoid arthritis". Met. Ions Biol. Syst. 41: 279–304. PMID 15206120.
  9. ^ Gaujoux-Viala C, Smolen JS, Landewé R, Dougados M, Kvien TK, Mola EM, Scholte-Voshaar M, van Riel P, Gossec L (June 2010). "Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis". Ann. Rheum. Dis. 69 (6): 1004–9. doi:10.1136/ard.2009.127225. PMID 20447954. S2CID 30886393.
  10. ^ Fuller FW (2009). "The side effects of silver sulfadiazine". J. Burn Care Res. 30 (3): 464–70. doi:10.1097/BCR.0b013e3181a28c9b. PMID 19349889. S2CID 3676574.
  11. ^ Carter MJ, Tingley-Kelley K, Warriner RA (October 2010). "Silver treatments and silver-impregnated dressings for the healing of leg wounds and ulcers: a systematic review and meta-analysis". J. Am. Acad. Dermatol. 63 (4): 668–79. doi:10.1016/j.jaad.2009.09.007. PMID 20471135.
  12. ^ Guthery E, Seal LA, Anderson EL (February 2005). "Zinc pyrithione in alcohol-based products for skin antisepsis: persistence of antimicrobial effects". Am J Infect Control. 33 (1): 15–22. doi:10.1016/j.ajic.2004.07.012. PMC 7119132. PMID 15685130.

Further reading